A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer.
- Resource Type
- journal article
- Source
- Targeted Oncology; Aug2017, Vol. 12 Issue 4, p463-474, 12p
- Subject
CELL receptors CLINICAL trials COMPARATIVE studies DOSE-effect relationship in pharmacology HETEROCYCLIC compounds LONGITUDINAL method LUNG cancer LUNG tumors RESEARCH methodology MEDICAL cooperation ORAL drug administration RESEARCH STOMACH tumors EVALUATION research - Language
- ISSN
- 17762596